Inflammatory bowel disease (IBD) is a chronic inflammatory condition thought to reflect a failure of the enteral immune system to adequately regulate itself. Inflammatory stress drives upregulation of heat-shock proteins (HSPs), including the pro-inflammatory chaperone, HSP90. This protein sequesters the transcription factor, heat-shock factor 1 (HSF1) in the cytoplasm preventing transcription of a number of anti-inflammatory proteins. We hypothesized that inhibition of HSP90 would exert an anti-inflammatory effect and thereby attenuate intestinal inflammation in murine models of IBD. Inhibition of HSP90 with 17-allylaminogeldanamycin (17-AAG) reduced inflammation in acute dextran sodium sulfate and chronic CD45RB
INTRODUCTION
Constant exposure of the gut mucosa to luminal antigens makes regulation of the inflammatory response crucial to maintaining a state of hyporesponsiveness. Animal studies indicate that CD4 þ CD25 þ Foxp3 þ regulatory T cells (Tregs) provide balance for the immune response in normal intestinal mucosa.
1,2 A breakdown of this tolerance has a pivotal role in the development of inflammatory bowel disease (IBD). 3 Both mice and humans with a defect in the forkhead box p3 (Foxp3) gene develop a wide range of autoimmune and inflammatory pathologies, including enteritis, providing evidence that this pathway may be relevant for intestinal homeostasis.
Previous studies using inhibitors of histone deacetylase (HDAC) to enhance Treg function and thereby attenuate murine colitis suggest a role for HDAC6-dependent regulation of heat-shock protein (HSP) 90. 4 Inducible HSPs are activated under conditions of cellular stress; these stresses include chemical, heat, hypoxia, and exposure to cytokines. These proteins, once expressed, act as chaperones to either allow for normal protein folding or to stabilize the protein and prevent degradation. Transcriptional activation of the heat-shock response requires release of heat-shock factor 1 (HSF1) from its chaperone HSP90 and trimerization of HSF1. It has previously been demonstrated that HSF1 and HSPs are involved in the repression of pro-inflammatory cytokines such as interleukin (IL)-1b, tumor-necrosis factor-a (TNFa), interferon-g (IFNg) [5] [6] [7] and activation of the anti-inflammatory gene IL-10. 8, 9 In genome-wide association studies, HSF1 and HSPs have been associated with IBD, 10, 11 generally as protective factors.
Inhibitors of HSP90 such as 17-allylaminogeldanamycin (17-AAG) have been shown to compete with ATP for binding to the N-terminus of the protein, causing release of HSF1 from the inhibitory complex with HSP90, thus allowing trimerization of HSF1 and translocation to the nucleus. 12 Nuclear HSF1 binds to heat-shock response elements and induces transcription of heat-shock response genes. 13 HSP90 inhibitors have proven effective in treatment of murine models of sepsis, 6 arthritis, 14 uveitis, 15 and multiple sclerosis, 16 but their potential in IBD has yet to be established. Here we examined the therapeutic benefit of 17-AAG, a potent inhibitor of HSP90, for the regulation of inflammation in two distinct murine models of colitis. First, we investigated whether inhibition of HSP90 affected colitis onset and severity. We next assessed if HSP90 inhibition could reverse established adoptive-transfer colitis. We then investigated the capacity of HSP90 inhibition to enhance Treg function ex vivo and thereby offer a Treg-dependent mechanism to modulate disease severity. Finally, we assessed the effect of HSP90 inhibition on nuclear translocation of HSF1 in activated Tregs and subsequent changes in gene transcription. Our data further define a role for the heat-shock response pathway (HSP90 and HSF1) in the maintenance of mucosal immune homeostasis.
RESULTS

HSP90 inhibition attenuates chemically induced acute murine colitis
In order to evaluate the role of HSP90 inhibition on chemically induced murine colitis 10-week-old wild-type mice were treated with HSP90 inhibitor 17-AAG or vehicle for 7 days while receiving DSS ad libitum in drinking water. Treatment with 17-AAG significantly attenuated weight loss (Po0.05) in the DSS colitis model as measured by repeated measures analysis of variance ( Figure 1a ). This effect coincided with a decreased colon shortening, a surrogate marker of colitis, in 17-AAG-treated mice (51 ± 2 mm; Po0.05) compared with vehicle (43±2 mm; Figure 1b) .
A pathologist who was blinded to the experimental conditions performed histological assessment of colitis, which identified a significant decrease in tissue injury from vehicletreated (5.8 ± 1.1) compared with 17-AAG (2.6 ± 0.4; Po0.01; Figure 1c ). Inflammation indices also decreased from vehicletreated (7.6 ± 0.8) compared with 17-AAG (4.7 ± 0.3; Po0.01; Figure 1c ). This reduction in tissue injury, loss of crypt architecture, and epithelial integrity along with the reduction in inflammatory infiltrate are depicted in the representative hematoxylin and eosin micrographs (Figure 1d ).
Increased anti-inflammatory cytokines and cells following HSP90 inhibition
To better understand the underlying mechanism by which HSP90 inhibition ameliorates inflammation, cytokine expression analysis was performed on colonic explants from DSS colitic mice treated with or without 17-AAG. These studies corroborated the histological evidence of attenuated inflammation, demonstrating a significant reduction in a number of inflammatory cytokines. Release of IL-2 decreased from 22.8 ± 1.2 pg ml À 1 from vehicle-treated mice to 15.7 ± 0.8 pg ml À 1 from 17-AAG-treated mice (Po0.001). IL-4 secretion decreased from 26.7±2.0 pg ml À 1 from vehicletreated mice to 9.9±0.8 pg ml À 1 from 17-AAG-treated mice (Po0.001). IL-17 secretion decreased from 440.4 ± 39.9 pg ml À 1 from vehicle-treated mice to 30.6 ± 4.2 pg ml À 1 from 17-AAG-treated mice (Po0.001). IFNg secretion decreased from 74.8 ± 8.6 pg ml À 1 from vehicle-treated mice to 38.2 ± 3.9 pg ml À 1 from 17-AAG-treated mice (Po0.01). Expression of IL-10 was significantly increased by 17-AAG administration with 445.6±44.4 pg ml À 1 released from vehicle-treated mice to 1704±239.1 pg ml À 1 in 17-AAG-treated mice (Po0.001), while release of TNFa was unaltered ( Figure 2a) . Similarly, expression of IL-1b and IL-6 were also not significantly altered (not shown). Cell populations were evaluated from both the DSS-treated groups to assess for the presence of CD4 þ Foxp3 þ cells. Lymphocytes were isolated from the spleen, MLN, and LP and evaluated by flow cytometry. We noted that there was an increase in the percentage of CD4
þ Foxp3 þ cells in the colonic LP of mice treated with 17-AAG (16% ± 2; Po0.05) compared with vehicle-treated mice (10% ± 0; Figure 2b ). In addition, we noted a significant increase in the percentage of CD4 þ Foxp3 þ cells in the MLN of 17-AAG-treated mice (14% ± 1; Po0.01) compared with vehicle-treated mice (7%±1; Figure 2c ). In summary, 17-AAG had a protective effect on the severity of DSS-mediated colitis partly mediated by decreased inflammatory cytokine production and increased frequency of Tregs.
Expression of HSP90 is increased during murine colitis
We evaluated the expression of HSP90 following induction of murine colitis to determine whether it was regulated by inflammation. Western blot analysis demonstrated a significant increase in expression of HSP90 relative to b-actin control in colitic tissue (1.5±0.02; Po0.05; Figure 3a ,b) compared with water-treated mice. This was consistent with immuno fluorescent assessment of HSP90 expression from colonic tissues of water control and DSS-treated mice. It demonstrates that in the absence of inflammation, HSP90 expression is largely restricted to the base of the crypts, whereas during colitis, expression is upregulated particularly at the mucosal surface ( Figure 3c ). Our data therefore suggests that there is an increase in HSP90 expression in response to DSS-induced epithelial injury and intestinal barrier disruption. Neg cells (Figure 4a) . Similarly, expression of HSP90b was also upregulated on Tregs (544±159 vs. 1214±64), whereas not significantly increased in non-Tregs. Thus, during heat shock or potentially inflammatory stress, both HSP90 isoforms are preferentially upregulated in Tregs.
Expression analysis of intracellular HSP90a and HSP90b by flow cytometry from wild-type mice demonstrated that both HSP90a and b isoforms were significantly upregulated on CD4
þ Foxp3 þ Tregs compared with non-Tregs freshly isolated from the spleen, MLN, and colonic LP (Figure 4c) . Furthermore, expression of both isoforms was greatest in the MLN followed by the LP and was significantly lower in the spleen (Figure 4d) . Thus, T-cell expression of HSP90 occurs preferentially on Tregs and appears to coincide with Treg activation.
HSP90 inhibition alleviates colitis in the CD45RB
High adoptive-transfer model As DSS colitis is not predominantly T-cell mediated, we used the adoptive-transfer model of colitis to address the role of HSP90 in a more T-cell-directed manner. To do this, naïve CD4 þ /CD45RB High cells were adoptively transferred into lymphopenic sex-matched recipients and development of colitis monitored indirectly by continuous assessment of body weight. 17-AAG-treated mice were protected from further significant weight loss and actually gained weight when treated with 17-AAG (101 ± 1%; Po0.001; Figure 5a ) compared with vehicle-treated mice (89±1%). Postmortem analysis revealed that 17-AAG-treated mice (71±4 mm; Po0.01) displayed significantly less colonic shortening compared with the vehicle control mice (60±2 mm; Figure 5b ). The protective effect of 17-AAG also resulted in a visible decrease in inflammation compared with vehicle controls. Active inflammatory indices decreased from vehicle-treated (7.8 ± 1; Figure 5c ) compared with 17-AAG-treated mice (2.6 ± 1; Po0.01). Similarly, chronic inflammatory indices decreased from vehicletreated (8.6±1) compared with 17-AAG-treated (4.6±1; Po0.01). Furthermore, total inflammatory indices significantly decreased from vehicle (16.4±1.5) compared with 17-AAG-treated mice (7.2 ± 1.4; Po0.001). Tissue from 17-AAG-treated mice also displayed significantly less disruption of crypt architecture as shown by representative hematoxylin and eosin micrographs ( Figure 5d ). This beneficial effect was lost when CD45RB
High adoptivetransfer colitis experiments were conducted using IL-10 À / À cells consistent with a pivotal role for increased IL-10 production in the therapeutic effect of 17-AAG (see Supplementary Figure S1 online). 
HSP90 inhibition promotes IL-10 production and Treg induction during chronic colitis
To assess the impact of HSP90 inhibition on cytokine production in this T-cell-dependent colitis model, multiplex cytokine analyses were performed on cultured explant tissues as before. Cytokine expression analysis from CD45RB
Highrecipient mice demonstrated a similar pattern to those of DSS colitic mice, with a significant decrease in IFNg from vehicle-treated controls (59 ± 7 pg ml ; Po0.01; Figure 6a ). Although TNFa production was higher from vehicle controls (283±58 pg ml Thereafter, cell populations were evaluated from the above adoptive-transfer colitis experiments, and treated groups were assessed for the presence of CD4 þ Foxp3 þ cells. Lymphocytes were isolated from the spleen, MLN, and colonic LP and evaluated by flow cytometry. Similar to our DSS experiments, we noted that there was an increase in the percentage of LP CD4 þ Foxp3 þ cells from vehicle-treated mice (3%±0; Figure 6b ) to mice treated with 17-AAG (5% ± 1; Po0.01). Moreover, we demonstrated a significant increase in IL-10 production by Tregs isolated from RAG1 À / À colitic mice treated with 17-AAG (18% ± 1; Figure 6d ) compared with vehicle controls (5% ± 0; Po0.001). Therefore, 17-AAG attenuated established colitis in this adoptive-transfer model and increased the presence of Tregs along with increasing their IL-10 production in the colonic LP. To further define the mechanism of 17-AAG-mediated enhanced Treg suppression, we repeated the Treg-suppression assays using cells from IL-10 À / À mice. As has been reported previously, IL-10 À / À Tregs have decreased suppressive function; however, more importantly, the enhancement seen with 17-AAG was abolished in the absence of IL-10. Therefore, the HSF1-dependent 17-AAG-mediated increased suppression appears to be IL-10 dependent as well (Figure 8 ). Figure 9a ) compared with vehicle controls. This increase corresponded with an upregulation of HSP90aa1, HSPA1A, and IL-10 at both 6 h and 24 h time-points, whereas HSP90ab1 was only induced at the early time-point and HSPA1B at the late time-point (Figure 9b) . Thus, HSP90 inhibition with 17-AAG promotes translocation of HSF1 to the nucleus with resultant upregulation of HSF1 response genes.
DISCUSSION
The heat-shock response has a critical role in regulating new protein synthesis in response to cellular stress, including during the induction of an inflammatory response. In this study, we identify a role of the heat-shock response in mucosal homeostasis via Treg control. Considerable progress has been made in recent years in understanding the basic biology of HSPs and, in particular, HSP90 signaling during inflammation; however, little is known about their role in the induction/maintenance of chronic intestinal inflammatory conditions, such as IBD. As such, this study aimed to investigate the effect of HSP90 inhibition in both acute and chronic murine models of IBD. Of particular interest was whether pharmacological targeting of HSP90 might be of therapeutic value. In this series of studies, we demonstrate that HSP90 inhibition with 17-AAG, which binds to the N-terminal ATPase, 17 attenuates both new-onset murine colitis using the DSS model and established colitis using the CD45RB
High adoptive-transfer model. Treatment with 17-AAG enhanced secretion of anti-inflammatory IL-10, increased Treg numbers and improved efficiency of Treg suppression in an HSF1-dependent manner.
Having first identified a successful outcome with HSP90 blockade for the attenuation of colitis, we sought to better understand the expression of HSP90 in response to an inflammatory stimulus. HSP90 expression was increased in response to DSS colitis consistent with previous studies in human IBD demonstrating an upregulation of HSP90 and HSP70 associated with ulcerative colitis, which was decreased by treatment with 5-aminosalicylic acid over 6 months. 18 Although HSP90 is a ubiquitously expressed protein, 19 we next sought to ascertain whether the upregulation of HSP90 was detectable in T cells. Flow cytometric analysis demonstrates that HSP90 isoforms are preferentially expressed on Foxp3 Based on these findings, we chose to focus on the therapeutic potential of 17-AAG in a T-cell-mediated colitis model using the CD45RB
High adoptive-transfer model 20 of IBD. Consistent with our previous findings, we observed an attenuation of inflammation in this model as well. Furthermore 17-AAG once again increased IL-10 production by Tregs along with Treg numbers while attenuating inflammation, pro-inflammatory cytokine secretion, and inflammatory cell infiltration into the colon. The increased expression of IL-10 may be sufficient to account for all of these observations as IL-10 has been shown previously to act as a growth factor for Tregs, 21 and Tregderived IL-10 is critical for attenuation of colitis in this model. 22 Similarly, we have observed a beneficial effect of increasing Treg frequency in IBD models previously. 23 Furthermore, in the absence of T-cell-derived IL-10, 17-AAG was unable to rescue the colitis in this model, consistent with this being a primary therapeutic mechanism of action.
Our lab has previously demonstrated that 17-AAG enhances Tregs suppressive function in vitro; 4 however, no mechanism of this enhancement was identified. Accurately identifying which protein chaperoned by HSP90 is altered in response to 17-AAG is difficult, as there are currently over 100 known client proteins for HSP90. 24 However, HSP90 does form a complex with HSP70, and HSP70 has been shown to attenuate murine arthritis via enhanced IL-10 production from Tregs so it is possible that inhibition of HSP90 increases the availability of HSP70, which then, in turn, enhances Treg function. 25 Furthermore 17-AAG upregulates expression of HSP70 mRNA 26 and overexpression of HSP70 has been shown to enhance Treg-suppressive function. 27 However, the ability of 17-AAG to drive HSP70 is actually HSF1-dependent, 28 and so we sought to determine if the enhanced suppressive function might also be HSF1 dependent.
Using HSF1 À / À cells, we demonstrated that enhanced suppressive function due to 17-AAG was abolished in the absence of HSF1 À / À . Pre-induction of the heat-shock response has been demonstrated previously to protect against acute murine colitis. 29 Although not identified at the time, the anti-inflammatory effect of heat shock is likely mediated by induction of the transcription factor HSF1. 30 HSF1 is known to drive expression of a number of anti-inflammatory genes, including IL-10 31 and HSP70, 32 while also suppressing albeit transiently pro-inflammatory gene expression, including IL-1b and TNFa. 33 HSP90 also forms an inhibitory complex with HSF1, preventing trimerization, nuclear translocation, and transcriptional activation by HSF1. 30 Inhibition of HSP90 therefore disrupts that complex, increasing HSF1 translocation to the nucleus and enhancing HSF1 transcriptional activation function. 12 This, in turn, acts as a negative regulator of proinflammatory cytokine gene transcription 34 and a positive signal for anti-inflammatory gene transcription. Therefore, it is likely that the anti-inflammatory effects of HSP90 inhibitors are, at least, partly mediated via release of HSF1. The expression of HSP90 is induced in response to heat shock or inflammatory stress 29 via STAT1 (signal transducer and activator of transcription factor 1)-dependent induction, 35 which may reflect a mechanism for limiting HSF1 activation. Pharmacological blockade of this endogenous braking mechanism may have therapeutic potential in overactive inflammatory diseases such as IBD, and indeed this has been borne out in other models of inflammation. Indeed, blockade of HSP90 has proven effective at attenuating inflammation in a number of autoimmune murine models via decreased expression of proinflammatory cytokines such as IL-1b 15, 16, 36 consistent with the anti-inflammatory effects seen in our studies.
Having demonstrated that the effect of 17-AAG on Treg suppression was HSF1-dependent, we then extended these observations even further to demonstrate that it was also mediated via increased IL-10 output as IL-10 À / À cells failed to display this enhanced suppressive function. These in vitro results are further supported by the suppression of adoptively transferred T-cell proliferation in CD45RB
High colitis. Furthermore, this is consistent with studies demonstrating enhanced Treg function in HDAC6 À / À mice, 4 coinciding with increased HSP90 acetylation correlated with impaired HSP90 function. 37 Based on our hypothesis that HSP90 inhibition with 17-AAG was driving IL-10 expression in a HSF1-dependent manner, we assessed the localization of HSF1 in activated Tregs treated with 17-AAG in vitro and demonstrated that, indeed, blockade of HSP90 caused a shift in HSF1 trimer to the nucleus and a subsequent mRNA upregulation of anti-inflammatory IL-10 and HSP70 isoforms (HSPA1A and HSPA1B) in isolated Tregs. These findings account for the enhanced suppressive function of Tregs treated with 17-AAG as well as the anti-inflammatory effect of 17-AAG in both IBD models tested. Interestingly, however, enhanced translocation of HSF1 to the nucleus also led to upregulation of HSP90a and HSP90b mRNA. We believe that this response is part of a negative feedback autoregulatory mechanism whereby HSF1 upregulated HSP90, which, in turn, sequesters HSF1 in the cytoplasm to prevent overactivation/ translocation of the HSF1 anti-inflammatory pathway and thereby reduce risk of opportunistic infection associated with excessive immunosuppression.
The ability of HSP90 inhibition to attenuate murine colitis makes them an attractive candidate for future clinical application in IBD. The ongoing trials of HSP90 inhibitors in cancer chemotherapy in which their safety and pharmacokinetics are firmly established further support the translation of this technology to an IBD context. Finally, as we increase our understanding of the anti-inflammatory mechanisms of HSP90 inhibition in murine models of IBD, these data provide proof of principle for the application of newer more effective HSP90 inhibitors currently in development to use in the treatment of IBD.
METHODS
Mice. A colony of C57/Bl6J mice were maintained in house kept under specific pathogen-free conditions. Foxp3-green fluorescent protein, RAG1
À / À (2216), IL-10 À / À (2251), and HSF1 À / À mice (129/SvEvTac; 10543) were obtained from Jackson laboratories (Bar Harbor, ME); HSF1 þ / þ littermates were used as controls for 
HSF1
À / À mice. Fecal samples from these mice were consistently negative for Helicobacter, protozoa, and helminthes. All animals were handled according to the procedures approved by the institutional committee for animal use.
Chemically induced acute murine colitis model. Mice were treated with dextran sodium sulfate (DSS) ad libitum (3% w/v; MP Biomedicals, Santa Ana, CA; 36-50 kDa) in drinking water for 7 d. Water alone groups were included as a control. DSS groups received daily intraperitoneal injections of 17-AAG (40 mg kg À 1 ) or vehicle dimethyl sulfoxide. Body weight, stool consistency, and occult bleeding were assessed daily to construct a disease activity index. At the time of killing, spleen, mesenteric lymph nodes (MLNs), and segments of colonic tissue were excised for flow cytometric analysis of leukocyte subsets, colon lengths were assessed and colon sections processed for histology, RNA extraction and cytokine analyses to assess disease activity. Histology was evaluated and scored by a trained pathologist blinded to the conditions of the experiments (PJ) according to a previously described scoring system. 38 Colonic tissues were snap frozen and homogenized in RIPA buffer or paraffin embedded for western blot and immunofluorescence, respectively, using anti-HSP90 antibody (C45G5; Cell Signaling; Danvers, MA) according to the manufacturers instructions. Lymphocyte isolation. Single-cell suspensions were obtained by gently pressing the MLN or spleen against a 70-mm cell strainer. Splenic red blood cells were lysed by 3 min incubation in ammonium chloride lysing reagent (ACK Lysis Buffer, Invitrogen, Carlsbad, CA). Intestinal segments were opened along the mesentery and rinsed of luminal contents with phosphate-buffered saline before cutting into 1 cm sections in phosphate-buffered saline containing 15 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) and 1 mM EDTA with vigorous agitation on a vortex mixer. The tissue was then passed through a 70-mm tissue strainer, and the process repeated until the wash remained clear. The remaining lamina propria (LP) was digested in 1 mg ml À 1 Collagenase Type VIII (Sigma Aldrich, St. Louis, MO, C9722) for 10 min in an orbital shaker at 270 r.p.m. and 37 1C. Tissues were vortexed briefly and filtered to remove any remaining undigested material and cells counted before flow cytometric evaluation.
Cytokine production assays. Tissue explants (0.5 cm 2 ) were cultured for 24 h in Dulbecco's modified Eagle's medium (without sodium pyruvate, Cellgro Manassas, VA, supplemented with 5% fetal bovine serum, 2 mM glutamine, 100 IU penicillin and 100 mg ml À 1 streptomycin; Invitrogen). Culture supernatants were then analyzed for the presence of cytokines using the Milliplex Cytokine Multiplex Assay system (Logan, UT). In vitro stimulation assays. Freshly isolated CD4 þ /CD25 þ Tregs from wild-type mice were stimulated with plate-bound anti-CD3 antibody (2 mg ml À 1 ; eBioscience) and soluble anti-CD28 (2 mg ml À 1 ; eBioscience) with (out) 17-AAG (250 nM) for either 6 or 24 h. Nuclear and cytoplasmic protein extracts were isolated after 6 h using the NE-PER extraction kit (Thermo Scientific, Rockford, IL) according to the manufacturer's instructions. Western blot of HSF1 (4356S, Cell Signaling) using both denaturing and non-denaturing conditions were performed on 4-15% gradient gels (Biorad, Hercules, CA). RNA was isolated from both timepoints using the RNeasy kit (Qiagen, Valencia, CA) before cDNA synthesis and realtime RT-PCR (Taqman Probes, Life Technologies, Grand Island, NY). Individual wells were internally controlled by multiplexing with VIC-labeled 18S Taqman probe.
Statistics. Statistical analyses were performed using Student's t-test or repeated measures analysis of variance with Graphpad Prism Data Analysis software (GraphPad Software, La Jolla, CA). Data were expressed as mean±s.e.m. Statistical significance was set at Po0.05.
